Please login to the form below

Not currently logged in
Email:
Password:

oral semaglutide

This page shows the latest oral semaglutide news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Trulicity scores CV reduction indication in the US

Lilly’s Trulicity scores CV reduction indication in the US

The new MACE approval could help Lilly in its fight for market share with other GLP-1 agonists, including Novo Nordisk’s once-weekly drug Ozempic (semaglutide). ... Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto

Latest news

  • New drugs drive Novo Nordisk despite insulin price pressures New drugs drive Novo Nordisk despite insulin price pressures

    This included a boost from GLP-1 agonist  Ozempic (semaglutide) which has been climbing solidly since its launch, as demand increases for the drug. ... Novo also reported sales of DKK50m for its recently launched oral semaglutide product  Rybelsus in

  • Givlaari, Rybelsus lead crowded CHMP recommendations Givlaari, Rybelsus lead crowded CHMP recommendations

    Joining Givlaari with a positive recommendation was  Rybelsus (semaglutide), Novo Nordisk’s once-daily oral formulation of its injectable GLP-1 agonist semaglutide.

  • Novo Nordisk gets MACE prevention claim for Ozempic in US Novo Nordisk gets MACE prevention claim for Ozempic in US

    At the same time, the FDA also updated the label for Novo Nordisk’s oral formulation of semaglutide – called Rybelsus – to reflect data from the PIONEER 6 study backing its cardiovascular ... For now, it’s the only GLP-1 drug on the market that

  • Novo bolstered by new diabetes, obesity products Novo bolstered by new diabetes, obesity products

    Also helping to bolster its sales and growth is new oral semaglutide drug Rybelsus, which received approval from the FDA in the US  recently. ... It is the first oral alternative to injectable GLP-1 agonists, and has also been touted by Novo as a

  • Novo Nordisk gets FDA okay for new diabetes hope Novo Nordisk gets FDA okay for new diabetes hope

    product. The US regulator has approved the Danish drugmaker’s  oral formulation of semaglutide under the Rybelsus brand name, extending its range of GLP-1 agonist drugs that include once-weekly ... In the Pioneer programme, people treated with oral

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Allergan’s Ubrelvy is the only other oral CGRP antagonist approved for acute migraine, which entered the market ahead of rimegepant. ... 7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    Novo Nordisk is also working with another specialist on oral delivery for protein drugs - Emisphere Technologies - that has applied its Eligen technology to develop an oral version of semaglutide, a ... rarely as once a quarter for example, which makes

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics